Alnylam Pharmaceuticals (ALNY) Target Lifted to $94 at Needham & Company

February 14, 2014 7:29 AM

Needham & Company analyst Alan Carr, Ph.D reiterated a Buy rating and raised his price target on Alnylam Pharmaceuticals (NASDAQ ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found